{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:04Z","timestamp":1787387044054,"version":"build-2736575974"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40273-026-01630-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:10:01Z","timestamp":1780413001000},"page":"1057-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4328-1433","authenticated-orcid":false,"given":"Kun Shi-van","family":"Wielink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret","family":"Dahlmann-Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thom W. L.","family":"de Milliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Croci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvraj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Punekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1630_CR1","unstructured":"World Health Organization. World report on vision [Internet] 2019. Available from: [https:\/\/iris.who.int\/bitstream\/handle\/10665\/328717\/9789241516570-eng.pdf?sequence=18]."},{"key":"1630_CR2","volume":"2","author":"JG Lawrenson","year":"2025","unstructured":"Lawrenson JG, Huntjens B, Virgili G, et al. Interventions for myopia control in children: a living systematic review and network meta\u2010analysis. Cochrane Database Syst Rev. 2025;2:CD014758.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1630_CR3","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","volume":"60","author":"DI Flitcroft","year":"2019","unstructured":"Flitcroft DI, He M, Jonas JB, et al. IMI\u2013defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20\u201330.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"1630_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2471\/BLT.08.055673","volume":"87","author":"T Smith","year":"2009","unstructured":"Smith T, Frick K, Holden B, Fricke T, Naidoo K. Potential lost productivity resulting from the global burden of uncorrected refractive error. Bull World Health Organ. 2009;87(6):431\u20137.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"1630_CR5","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/bjo-2024-325427","volume":"109","author":"J Liang","year":"2025","unstructured":"Liang J, Pu Y, Chen J, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 2025;109(3):362\u201371.","journal-title":"Br J Ophthalmol"},{"key":"1630_CR6","volume":"54","author":"A Moreira-Ros\u00e1rio","year":"2025","unstructured":"Moreira-Ros\u00e1rio A, Lanca C, Grzybowski A. Prevalence of myopia in Europe: a systematic review and meta-analysis of data from 14 countries. Lancet Reg Health. 2025;54:101319.","journal-title":"Lancet Reg Health"},{"issue":"3","key":"1630_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.optom.2019.06.002","volume":"13","author":"K Wong","year":"2020","unstructured":"Wong K, Dahlmann-Noor A. Myopia and its progression in children in London, UK: a retrospective evaluation. J Optom. 2020;13(3):146\u201354.","journal-title":"J Optom"},{"key":"1630_CR8","doi-asserted-by":"crossref","unstructured":"Kynman-Sprinks D, Biswas S, Logan NS, Wolffsohn JS. 125959 Future projections of myopia in the UK and Ireland: trends in prevalence, progression, and pathology through 2050. BMJ Publishing Group Ltd; 2025.","DOI":"10.1136\/bmjophth-2025-BIPOSA.45"},{"key":"1630_CR9","unstructured":"American Optometric Association. Optometric clinical practice guideline. Care of the patient with myopia 2006. Available from: [https:\/\/www.aoa.org\/AOA\/Documents\/Practice%20Management\/Clinical%20Guidelines\/Consensus-based%20guidelines\/Care%20of%20Patient%20with%20Myopia.pdf]."},{"key":"1630_CR10","unstructured":"Cooper Y. With childhood myopia rates on the rise, the American Optometric Association highlights the importance of early intervention through annual eye exams 2019. Available from: [https:\/\/www.aoa.org\/about-the-aoa\/press-room\/press-releases\/myopia-rates-on-the-rise]."},{"key":"1630_CR11","unstructured":"Yoo SH. Myopia (nearsightedness) in children & teens: American Academy of Pediatrics; 2023. Available from: [https:\/\/www.healthychildren.org\/English\/health-issues\/conditions\/eyes\/Pages\/Myopia-Nearsightedness.aspx]."},{"issue":"5","key":"1630_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1600-0420.1995.tb00294.x","volume":"73","author":"H Jensen","year":"1995","unstructured":"Jensen H. Myopia in teenagers: an eight\u2010year follow\u2010up study on myopia progression and risk factors. Acta Ophthalmol Scand. 1995;73(5):389\u201393.","journal-title":"Acta Ophthalmol Scand"},{"issue":"9","key":"1630_CR13","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.66.9.7","volume":"66","author":"D Jones","year":"2025","unstructured":"Jones D, Chow A, Fadel D, et al. IMI-instrumentation for myopia management. Invest Ophthalmol Vis Sci. 2025;66(9):7.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1630_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/iovs.66.12.27","volume":"66","author":"N Tahhan","year":"2025","unstructured":"Tahhan N, Bullimore MA, He X, et al. IMI-2025 Digest. Invest Ophthalmol Vis Sci. 2025;66(12):27.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1630_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaophthalmol.2016.4009","volume":"134","author":"JWL Tideman","year":"2016","unstructured":"Tideman JWL, Snabel MC, Tedja MS, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA ophthalmol. 2016;134(12):1355\u201363.","journal-title":"JAMA ophthalmol."},{"issue":"13","key":"1630_CR16","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1167\/iovs.13-12403","volume":"54","author":"COMET group","year":"2013","unstructured":"COMET group. Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET). Invest Ophthalmol Vis Sci. 2013;54(13):7871\u201384.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1630_CR17","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1038\/s41598-022-06898-x","volume":"12","author":"M Takeuchi","year":"2022","unstructured":"Takeuchi M, Meguro A, Yoshida M, et al. Longitudinal analysis of 5-year refractive changes in a large Japanese population. Sci Rep. 2022;12(1):2879.","journal-title":"Sci Rep"},{"key":"1630_CR18","unstructured":"American Optometric Association. Clinical report: myopia management 2021. Available from: [https:\/\/global.vtivision.com\/wp-content\/uploads\/sites\/4\/2023\/04\/Evidenced-Based-Optometry-Myopia-Clinical-Report.pdf]."},{"issue":"1","key":"1630_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00417-021-05372-0","volume":"260","author":"I Flores-Moreno","year":"2022","unstructured":"Flores-Moreno I, Puertas M, Almaz\u00e1n-Alonso E, et al. Pathologic myopia and severe pathologic myopia: correlation with axial length. Graefes Arch Clin Exp Ophthalmol. 2022;260(1):133\u201340.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1630_CR20","doi-asserted-by":"crossref","unstructured":"Tapaszt\u00f3 B, Flitcroft DI, Aclimandos WA, et al. Myopia management algorithm. Annexe to the article titled Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2024;34(4):952-966.","DOI":"10.1177\/11206721231219532"},{"issue":"13","key":"1630_CR21","first-page":"3636","volume":"55","author":"M Jong","year":"2014","unstructured":"Jong M, He M, Holden BA, et al. The rate of myopia progression in children who become highly myopic. Invest Ophthalmol Vis Sci. 2014;55(13):3636\u20133636.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1630_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/aos.13964","volume":"97","author":"O P\u00e4rssinen","year":"2019","unstructured":"P\u00e4rssinen O, Kauppinen M. Risk factors for high myopia: a 22-year follow-up study from childhood to adulthood. Acta Ophthalmol. 2019;97(5):510\u20138.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"1630_CR23","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.4.17","volume":"62","author":"C Lanca","year":"2021","unstructured":"Lanca C, Foo LL, Ang M, et al. Rapid myopic progression in childhood is associated with teenage high myopia. Invest Ophthalmol Vis Sci. 2021;62(4):17.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"1630_CR24","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.4103\/ijo.IJO_653_22","volume":"70","author":"M Rathi","year":"2022","unstructured":"Rathi M, Chhabra S, Sachdeva S, Rustagi IM, Soni D, Dhania S. Correlation of parental and childhood myopia in children aged 5-16 years in North India. Indian J Ophthalmol. 2022;70(9):3366\u20138.","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"1630_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaophthalmol.2015.0471","volume":"133","author":"K Zadnik","year":"2015","unstructured":"Zadnik K, Sinnott LT, Cotter SA, et al. Prediction of Juvenile-Onset Myopia. JAMA ophthalmol. 2015;133(6):683\u20139.","journal-title":"JAMA ophthalmol."},{"issue":"1","key":"1630_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1167\/iovs.09-4826","volume":"52","author":"DO Mutti","year":"2011","unstructured":"Mutti DO, Sinnott LT, Mitchell GL, et al. Relative peripheral refractive error and the risk of onset and progression of myopia in children. Invest Ophthalmol Vis Sci. 2011;52(1):199\u2013205.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1630_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.62.5.2","volume":"62","author":"P Sankaridurg","year":"2021","unstructured":"Sankaridurg P, Tahhan N, Kandel H, et al. IMI impact of myopia. Invest Ophthalmol Vis Sci. 2021;62(5):2\u20132.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"1630_CR28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/02713683.2023.2250581","volume":"48","author":"X Han","year":"2023","unstructured":"Han X, Ruan X, Zhang Y, et al. Effect of myopia severity on the health-related quality of life in children and their parents. Curr Eye Res. 2023;48(12):1189\u201394.","journal-title":"Curr Eye Res"},{"issue":"1","key":"1630_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tjo.2015.12.001","volume":"6","author":"MH Hsieh","year":"2016","unstructured":"Hsieh MH, Lin JC. Association of refractive error with vision-related quality of life in junior high school students. Taiwan J Ophthalmol. 2016;6(1):32\u20135.","journal-title":"Taiwan J Ophthalmol"},{"issue":"1","key":"1630_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12886-024-03533-3","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y, Chen L, Li P, Kang H, Tao Y. Risk factors and prognostic factors associated with retinal detachment and visual outcomes in acute retinal necrosis. BMC Ophthalmol. 2024;24(1):296.","journal-title":"BMC Ophthalmol"},{"issue":"10","key":"1630_CR31","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ophtha.2022.05.020","volume":"129","author":"D Li","year":"2022","unstructured":"Li D, Chan VF, Virgili G, et al. Impact of vision impairment and ocular morbidity and their treatment on depression and anxiety in children: a systematic review. Ophthalmology. 2022;129(10):1152\u201370.","journal-title":"Ophthalmology"},{"key":"1630_CR32","unstructured":"Dwight Akerman. Myopic children more likely to have depression and anxiety 2022. Available from: [https:\/\/reviewofmm.com\/myopic-children-more-likely-to-have-depression-and-anxiety\/]."},{"key":"1630_CR33","unstructured":"Katz L, Berlin KS. Psychological stress in childhood and myopia development. Optom Vis Perform. 2014;2(6)."},{"issue":"2","key":"1630_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/ICL.0b013e3182480e97","volume":"38","author":"A Queir\u00f3s","year":"2012","unstructured":"Queir\u00f3s A, Villa-Collar C, Guti\u00e9rrez AR, Jorge J, Gonz\u00e1lez-M\u00e9ijome JM. Quality of life of myopic subjects with different methods of visual correction using the NEI RQL-42 questionnaire. Eye Contact Lens. 2012;38(2):116\u201321.","journal-title":"Eye Contact Lens"},{"issue":"3","key":"1630_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/1120672121998960","volume":"31","author":"J N\u00e9meth","year":"2021","unstructured":"N\u00e9meth J, Tapaszt\u00f3 B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853\u201383.","journal-title":"Eur J Ophthalmol"},{"issue":"11","key":"1630_CR36","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","volume":"128","author":"MA Bullimore","year":"2021","unstructured":"Bullimore MA, Ritchey ER, Shah S, Leveziel N, Bourne RR, Flitcroft DI. The risks and benefits of myopia control. Ophthalmology. 2021;128(11):1561\u201379.","journal-title":"Ophthalmology"},{"issue":"4","key":"1630_CR37","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1097\/IAE.0b013e3181cf5c80","volume":"30","author":"AS Bansal","year":"2010","unstructured":"Bansal AS, Hubbard GB III. Peripheral retinal findings in highly myopic children\u2264 10 years of age. Retina. 2010;30(4):S15\u20139.","journal-title":"Retina"},{"issue":"6","key":"1630_CR38","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/opo.12082","volume":"33","author":"SC Cheng","year":"2013","unstructured":"Cheng SC, Lam CS, Yap MK. Prevalence of myopia\u2010related retinal changes among 12\u201318 year old H ong K ong C hinese high myopes. Ophthalmic Physiol Opt. 2013;33(6):652\u201360.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"6","key":"1630_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41433-023-02831-2","volume":"38","author":"KS Chen","year":"2024","unstructured":"Chen KS, Au Eong JTW, Au Eong K-G. Changing paradigm in the management of childhood myopia. Eye. 2024;38(6):1027\u20138.","journal-title":"Eye"},{"issue":"6","key":"1630_CR40","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.preteyeres.2012.06.004","volume":"31","author":"DI Flitcroft","year":"2012","unstructured":"Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res. 2012;31(6):622\u201360.","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"1630_CR41","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/opo.13381","volume":"44","author":"AH Dahlmann-Noor","year":"2024","unstructured":"Dahlmann-Noor AH, Ghorbani-Mojarrad N, Williams KM, et al. 2024 UK and Ireland modified Delphi consensus on myopia management in children and young people. Ophthalmic Physiol Opt. 2024;44(7):1368\u201391.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"6","key":"1630_CR42","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s40123-024-00951-w","volume":"13","author":"LS Eppenberger","year":"2024","unstructured":"Eppenberger LS, Grzybowski A, Schmetterer L, Ang M. Myopia control: are we ready for an evidence based approach? Ophthalmol Ther. 2024;13(6):1453\u201377.","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"1630_CR43","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jama.2015.10803","volume":"314","author":"M He","year":"2015","unstructured":"He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at school on the development of myopia among children in China: a randomized clinical trial. JAMA. 2015;314(11):1142\u20138.","journal-title":"JAMA"},{"issue":"5","key":"1630_CR44","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2012.11.009","volume":"120","author":"PC Wu","year":"2013","unstructured":"Wu PC, Tsai CL, Wu HL, Yang YH, Kuo HK. Outdoor activity during class recess reduces myopia onset and progression in school children. Ophthalmology. 2013;120(5):1080\u20135.","journal-title":"Ophthalmology"},{"issue":"8","key":"1630_CR45","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ophtha.2007.12.019","volume":"115","author":"KA Rose","year":"2008","unstructured":"Rose KA, Morgan IG, Ip J, et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115(8):1279\u201385.","journal-title":"Ophthalmology"},{"issue":"8","key":"1630_CR46","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1167\/iovs.06-1118","volume":"48","author":"LA Jones","year":"2007","unstructured":"Jones LA, Sinnott LT, Mutti DO, Mitchell GL, Moeschberger ML, Zadnik K. Parental history of myopia, sports and outdoor activities, and future myopia. Invest Ophthalmol Vis Sci. 2007;48(8):3524\u201332.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1630_CR47","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12886-015-0052-9","volume":"15","author":"JX Jin","year":"2015","unstructured":"Jin JX, Hua WJ, Jiang X, et al. Effect of outdoor activity on myopia onset and progression in school-aged children in northeast China: the Sujiatun Eye Care Study. BMC Ophthalmol. 2015;15:73.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1630_CR48","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bjophthalmol-2018-313739","volume":"104","author":"CSY Lam","year":"2020","unstructured":"Lam CSY, Tang WC, Tse DY, et al. Defocus incorporated multiple segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1630_CR49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaophthalmol.2022.0401","volume":"140","author":"J Bao","year":"2022","unstructured":"Bao J, Huang Y, Li X, et al. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA ophthalmol. 2022;140(5):472\u20138.","journal-title":"JAMA ophthalmol."},{"issue":"1","key":"1630_CR50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/bjophthalmol-2013-303914","volume":"98","author":"CS Lam","year":"2014","unstructured":"Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus incorporated soft contact (DISC) lens slows myopia progression in Hong Kong Chinese school children: a 2-year randomised clinical trial. Br J Ophthalmol. 2014;98(1):40\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1630_CR51","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/OPX.0000000000001410","volume":"96","author":"P Chamberlain","year":"2019","unstructured":"Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96(8):556\u201367.","journal-title":"Optom Vis Sci"},{"issue":"6","key":"1630_CR52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2020.10834","volume":"324","author":"JJ Walline","year":"2020","unstructured":"Walline JJ, Walker MK, Mutti DO, et al. Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. JAMA. 2020;324(6):571\u201380.","journal-title":"JAMA"},{"issue":"7","key":"1630_CR53","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1167\/iovs.11-8453","volume":"53","author":"T Hiraoka","year":"2012","unstructured":"Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. Invest Ophthalmol Vis Sci. 2012;53(7):3913\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1630_CR54","unstructured":"Higginbotham J, Kadri-Langford R. Is Myopia Management Available on the NHS? 2026. Available from: [https:\/\/www.myopiafocus.org\/myopia-management-on-nhs]."},{"issue":"4","key":"1630_CR55","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang J, Wen D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123(4):697\u2013708.","journal-title":"Ophthalmology"},{"issue":"11","key":"1630_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40986","volume":"6","author":"S Agyekum","year":"2023","unstructured":"Agyekum S, Chan PP, Adjei PE, et al. Cost-effectiveness analysis of myopia progression interventions in children. JAMA Netw Open. 2023;6(11):e2340986.","journal-title":"JAMA Netw Open"},{"key":"1630_CR57","doi-asserted-by":"crossref","unstructured":"Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113-124.","DOI":"10.1016\/j.ophtha.2018.05.029"},{"issue":"9","key":"1630_CR58","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1167\/iovs.14-14716","volume":"56","author":"A Kumaran","year":"2015","unstructured":"Kumaran A, Htoon HM, Tan D, Chia A. Analysis of changes in refraction and biometry of atropine-and placebo-treated eyes. Invest Ophthalmol Vis Sci. 2015;56(9):5650\u20135.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"1630_CR59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391\u20139.","journal-title":"Ophthalmology"},{"key":"1630_CR60","doi-asserted-by":"crossref","unstructured":"Chia A, Chua W-H, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157(2):451-457. e451.","DOI":"10.1016\/j.ajo.2013.09.020"},{"issue":"1","key":"1630_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","volume":"33","author":"P-C Wu","year":"2019","unstructured":"Wu P-C, Chuang M-N, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye. 2019;33(1):3\u201313.","journal-title":"Eye"},{"issue":"2","key":"1630_CR62","doi-asserted-by":"publisher","first-page":"176","DOI":"10.7150\/ijms.39365","volume":"17","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Tang Y, Guo L, et al. Efficacy and safety of 1% atropine on retardation of moderate myopia progression in Chinese school children. Int J Med Sci. 2020;17(2):176\u201381.","journal-title":"Int J Med Sci"},{"key":"1630_CR63","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","volume":"65","author":"O Hieda","year":"2021","unstructured":"Hieda O, Hiraoka T, Fujikado T, et al. Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study. Jpn J Ophthalmol. 2021;65:315\u201325.","journal-title":"Jpn J Ophthalmol"},{"issue":"10","key":"1630_CR64","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/j.jfo.2021.07.005","volume":"44","author":"M Moriche-Carretero","year":"2021","unstructured":"Moriche-Carretero M, Revilla-Amores R, Diaz-Valle D, Morales-Fern\u00e1ndez L, Gomez-de-Lia\u00f1o R. Myopia progression and axial elongation in Spanish children: efficacy of atropine 0.01% eye-drops. J Fr Ophtalmol. 2021;44(10):1499\u2013504.","journal-title":"J Fr Ophtalmol"},{"issue":"11","key":"1630_CR65","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li S-M, An W, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA ophthalmol. 2020;138(11):1178\u201384.","journal-title":"JAMA ophthalmol."},{"issue":"13","key":"1630_CR66","first-page":"3329","volume":"43","author":"W Chua","year":"2002","unstructured":"Chua W, Balakrishnan V, YCSG. Analysis of safety data for atropine in the treatment of myopia (ATOM) study. Invest Ophthalmol Vis Sci. 2002;43(13):3329\u20133329.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1630_CR67","unstructured":"European Medicines Agency. Ryjunea (atropine): Summary of product characteristics (SmPC) 2025. Updated 11 September 2025. Available from: [https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ryjunea-epar-product-information_en.pdf]."},{"key":"1630_CR68","unstructured":"European Medicines Agency. Ryjunea (atropine): Summary of opinion (initial authorisation) 2025. Updated 27 March 2025. Available from: [https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-positive-opinion-ryjunea_en.pdf]."},{"issue":"8","key":"1630_CR69","first-page":"2825","volume":"66","author":"P Johnson","year":"2025","unstructured":"Johnson P, Widder K, Cheetham J, Kirkeby L. Methods and baseline of a large, multicenter, phase 3 study with low-dose atropine (SYD-101) for the treatment of myopia progression in over 800 children (STAR Study). Invest Ophthalmol Vis Sci. 2025;66(8):2825\u20132825.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1630_CR70","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/opo.70007","volume":"45","author":"E Dow","year":"2025","unstructured":"Dow E, Day M, Kearney S. The prevalence and costs of optical correction for childhood myopia in Scotland. Ophthalmic Physiol Opt. 2025;45(7):1894\u2013904.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"1","key":"1630_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-025-00632-w","volume":"23","author":"H Bennett","year":"2025","unstructured":"Bennett H, Britton A, O\u2019Sullivan D, Lado F. Cost-effectiveness of myopia-control spectacles and contact lenses for children and adolescents in Wales. Cost Effect Resour Alloc. 2025;23(1):26.","journal-title":"Cost Effect Resour Alloc"},{"key":"1630_CR72","unstructured":"Review of myopia management. My U.K. Experience with Myopia Management 2021. Available from: [https:\/\/reviewofmm.com\/my-u-k-experience-with-myopia-management\/]."},{"key":"1630_CR73","unstructured":"eyesight. EyeDream: Ortho-K Vision Correction 2024. Available from: [https:\/\/www.eyesite.co.uk\/contact-lenses\/ortho-k-eyedream-vision-correction]."},{"issue":"12","key":"1630_CR74","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.1167\/iovs.13-12795","volume":"54","author":"Y-F Zheng","year":"2013","unstructured":"Zheng Y-F, Pan C-W, Chay J, Wong TY, Finkelstein E, Saw S-M. The economic cost of myopia in adults aged over 40 years in Singapore. Invest Ophthalmol Vis Sci. 2013;54(12):7532\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1630_CR75","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/eye.2008.225","volume":"23","author":"M Lim","year":"2009","unstructured":"Lim M, Gazzard G, Sim E, Tong L, Saw S. Direct costs of myopia in Singapore. Eye Lond. 2009;23(5):1086\u20139.","journal-title":"Eye Lond"},{"key":"1630_CR76","doi-asserted-by":"publisher","first-page":"728","DOI":"10.2471\/BLT.12.104034","volume":"90","author":"T Fricke","year":"2012","unstructured":"Fricke T, Holden B, Wilson D, et al. Global cost of correcting vision impairment from uncorrected refractive error. Bull World Health Organ. 2012;90:728\u201338.","journal-title":"Bull World Health Organ"},{"key":"1630_CR77","unstructured":"The College of Optometrists. MHRA approves first licensed low-dose atropine treatment for childhood myopia in the UK 2025. Available from: [https:\/\/www.college-optometrists.org\/news\/2025\/november\/mhra-licensed-low-dose-atropine-myopia]."},{"issue":"4","key":"1630_CR78","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/ceo.12206","volume":"42","author":"GL Kanthan","year":"2014","unstructured":"Kanthan GL, Mitchell P, Rochtchina E, Cumming RG, Wang JJ. Myopia and the long-term incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Clin Exp Ophthalmol. 2014;42(4):347\u201353.","journal-title":"Clin Exp Ophthalmol"},{"issue":"7","key":"1630_CR79","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/bjophthalmol-2021-320644","volume":"107","author":"YX Wang","year":"2023","unstructured":"Wang YX, Yang H, Wei CC, Xu L, Wei WB, Jonas JB. High myopia as risk factor for the 10-year incidence of open-angle glaucoma in the Beijing Eye Study. Br J Ophthalmol. 2023;107(7):935\u201340.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"1630_CR80","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.14246","volume":"98","author":"N Leveziel","year":"2020","unstructured":"Leveziel N, Marillet S, Dufour Q, et al. Prevalence of macular complications related to myopia - Results of a multicenter evaluation of myopic patients in eye clinics in France. Acta Ophthalmol. 2020;98(2):e245\u201351.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1630_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35520-x","volume":"13","author":"CA Ludwig","year":"2023","unstructured":"Ludwig CA, Vail D, Al-Moujahed A, et al. Epidemiology of rhegmatogenous retinal detachment in commercially insured myopes in the United States. Sci Rep. 2023;13(1):9430.","journal-title":"Sci Rep"},{"key":"1630_CR82","unstructured":"SSA.gov. Disability evaluation under social security, 2.00 special senses and speech - adult [Internet] 2024. Available from: [https:\/\/www.ssa.gov\/disability\/professionals\/bluebook\/2.00-SpecialSensesandSpeech-Adult.htm]."},{"issue":"4","key":"1630_CR83","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1167\/iovs.13-13675","volume":"55","author":"L Deng","year":"2014","unstructured":"Deng L, Gwiazda J, Manny RE, et al. Limited change in anisometropia and aniso-axial length over 13 years in myopic children enrolled in the Correction of Myopia Evaluation Trial. Invest Ophthalmol Vis Sci. 2014;55(4):2097\u2013105.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1630_CR84","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual [Internet]. Process methods [PMG36] 2022. Available from: [https:\/\/www.nice.org.uk\/process\/pmg36]."},{"issue":"6","key":"1630_CR85","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","volume":"15","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20133. Value Health. 2012;15(6):812\u201320.","journal-title":"Value Health."},{"key":"1630_CR86","unstructured":"National Institute for Health and Care Excellence (NICE). Health Technology Evaluation. Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517] 2025. Available from: [https:\/\/www.nice.org.uk\/guidance\/gid-ta11669\/documents\/scope-consultation-comments-and-responses]."},{"issue":"4","key":"1630_CR87","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1630_CR88","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC B\u00fcy\u00fckkaramikli","year":"2019","unstructured":"B\u00fcy\u00fckkaramikli NC, Rutten-van M\u00f6lken M, Severens JL, Al M. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391\u2013408.","journal-title":"Pharmacoeconomics"},{"key":"1630_CR89","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2147\/OPTH.S362342","volume":"16","author":"CY Hong","year":"2022","unstructured":"Hong CY, Boyd M, Wilson G, Hong SC. Photorefraction screening plus atropine treatment for myopia is cost-effective: a proof-of-concept Markov analysis. Clin Ophthalmol. 2022;16:1941\u201352.","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"1630_CR90","first-page":"821","volume":"64","author":"S Agyekum","year":"2023","unstructured":"Agyekum S, Zhang XJ, Chan PPM, et al. Cost-Effectiveness Analysis of Atropine for Treating Myopia Progression in Children. Invest Ophthalmol Vis Sci. 2023;64(8):821\u2013821.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1630_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3928\/1081597X-20211007-01","volume":"38","author":"M Balgos","year":"2022","unstructured":"Balgos M, Pi\u00f1ero DP, Canto-Cerdan M, Ali\u00f3 del Barrio JL, Ali\u00f3 JL. Comparison of the cost-effectiveness of SMILE, FS-LASIK, and PRK for myopia in a private eye center in Spain. J Refract Surg. 2022;38(1):21\u20136.","journal-title":"J Refract Surg"},{"key":"1630_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.750132","volume":"8","author":"Z Cui","year":"2021","unstructured":"Cui Z, Zhou W, Chang Q, et al. Cost-Effectiveness of Conbercept vs Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model. Front Med (Lausanne). 2021;8:750132.","journal-title":"Front Med (Lausanne)."},{"issue":"7","key":"1630_CR93","doi-asserted-by":"publisher","first-page":"A505","DOI":"10.1016\/j.jval.2013.08.1162","volume":"16","author":"C Leteneux","year":"2013","unstructured":"Leteneux C, Claxton L, Malcolm W, Taylor M, Rathi H. Cost-effectiveness of Ranibizumab for the treatment of visual impairment due to choroidal neovascularization secondary to pathologic myopia in the United Kingdom. Value Health. 2013;16(7):A505.","journal-title":"Value Health"},{"issue":"Suppl 7(6)","key":"1630_CR94","first-page":"34","volume":"29","author":"J Lian","year":"2023","unstructured":"Lian J, McGhee SM, Yap MKH, Sum R. Cost-effectiveness of myopia control by use of defocus incorporated multiple segments lenses: Abridged secondary publication. Hong Kong Med J. 2023;29(Suppl 7(6)):34\u20136.","journal-title":"Hong Kong Med J"},{"key":"1630_CR95","first-page":"S601","volume":"22","author":"J Liu","year":"2019","unstructured":"Liu J, Xie S, Ni W, He X, Ren X, Wu J. PDG26 cost-effectiveness of ranibizumab versus verteporfin photodynamic therapy in the treatment of choroidal neovascularization secondary to pathological myopia: from Chinese societal perspective. Value Health. 2019;22:S601.","journal-title":"Value Health"},{"key":"1630_CR96","doi-asserted-by":"crossref","unstructured":"Zhang L, Lin Z, Zhang W, Xuan J. Cost-effectiveness analysis of conbercept versus ranibizumab for the treatment of myopic choroidal neovascularization (CNV) in China. ISPOR Europe 2019. 2019.","DOI":"10.1016\/j.jval.2019.09.2566"},{"key":"1630_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100837","author":"R Li","year":"2023","unstructured":"Li R, Zhang K, Li S-M, et al. Implementing a digital comprehensive myopia prevention and control strategy for children and adolescents in China: A cost-effectiveness analysis. Lancet Reg Health West Pac. 2023. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100837.","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"1630_CR98","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2214-109X(22)00554-X","volume":"11","author":"H Liu","year":"2023","unstructured":"Liu H, Li R, Zhang Y, et al. Economic evaluation of combined population-based screening for multiple blindness-causing eye diseases in China: a cost-effectiveness analysis. Lancet Glob Health. 2023;11(3):e456\u201365.","journal-title":"Lancet Glob Health"},{"issue":"7","key":"1630_CR99","doi-asserted-by":"publisher","first-page":"A503","DOI":"10.1016\/j.jval.2013.08.1149","volume":"16","author":"W Malcolm","year":"2013","unstructured":"Malcolm W, Leteneux C, Claxton L, Taylor M, Rathi H. The budget impact of introducing Ranibizumab in England and Wales for the treatment of visual impairment due to choroidal neovascularization secondary to pathologic myopia. Value Health. 2013;16(7):A503.","journal-title":"Value Health"},{"key":"1630_CR100","unstructured":"Sydnexis Inc. The safety and efficacy of SYD-101 in children with myopia (STAR) [unpublished clinical trial data]. Data on file. 2025."},{"issue":"4","key":"1630_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AE Haarman","year":"2020","unstructured":"Haarman AE, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJ, Klaver CC. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49\u201349.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1630_CR102","unstructured":"American Academy of Ophthalmology. What are cataracts? [Internet] 2024. Available from: [https:\/\/www.aao.org\/eye-health\/diseases\/what-are-cataracts]."},{"issue":"5","key":"1630_CR103","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ophtha.2007.07.008","volume":"115","author":"GL Kanthan","year":"2008","unstructured":"Kanthan GL, Wang JJ, Rochtchina E, et al. Ten-year incidence of age-related cataract and cataract surgery in an older Australian population. The Blue Mountains Eye Study. Ophthalmology. 2008;115(5):808-814.e801.","journal-title":"Ophthalmology"},{"issue":"8","key":"1630_CR104","first-page":"3080","volume":"62","author":"A Abdelhady","year":"2021","unstructured":"Abdelhady A, Gaughan J, Schorr C. The prevalence of retinal detachment and associated comorbidities over a 5-year period. Invest Ophthalmol Vis Sci. 2021;62(8):3080\u20133080.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1630_CR105","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/bjophthalmol-2017-311266","volume":"102","author":"TR Fricke","year":"2018","unstructured":"Fricke TR, Jong M, Naidoo KS, et al. Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling. Br J Ophthalmol. 2018;102(7):855\u201362.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1630_CR106","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12913-018-2836-0","volume":"18","author":"L Pezzullo","year":"2018","unstructured":"Pezzullo L, Streatfeild J, Simkiss P, Shickle D. The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18(1):63.","journal-title":"BMC Health Serv Res"},{"key":"1630_CR107","unstructured":"Office for National Statistics (ONS). National life tables: England and Wales 2020\/22 [Internet]. 2024. Available from: [https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesenglandandwalesreferencetables]."},{"issue":"1","key":"1630_CR108","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ophtha.2017.06.019","volume":"125","author":"NA Yannuzzi","year":"2018","unstructured":"Yannuzzi NA, Chang JS, Brown GC, Smiddy WE. Cost-utility of evaluation for posterior vitreous detachment and prophylaxis of retinal detachment. Ophthalmology. 2018;125(1):43\u201350.","journal-title":"Ophthalmology"},{"key":"1630_CR109","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04183","volume":"14","author":"C So","year":"2024","unstructured":"So C, Lian J, McGhee SM, Sum RWM, Lam AKC, Yap MKH. Lifetime cost-effectiveness of myopia control intervention for the children population. J Glob Health. 2024;14:04183.","journal-title":"J Glob Health"},{"issue":"11","key":"1630_CR110","doi-asserted-by":"publisher","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","volume":"3","author":"JA Salomon","year":"2015","unstructured":"Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health. 2015;3(11):e712-723.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1630_CR111","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0039-6257(02)00457-5","volume":"48","author":"MM Brown","year":"2003","unstructured":"Brown MM, Brown GC, Sharma S, Landy J. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48(2):204\u201323.","journal-title":"Surv Ophthalmol"},{"key":"1630_CR112","first-page":"473","volume":"97","author":"GC Brown","year":"1999","unstructured":"Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc. 1999;97:473\u2013511.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1630_CR113","unstructured":"National Institute for Health and Care Excellence (NICE). Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. Technology appraisal guidance [TA298] 2013. Updated 20 May 2024. Available from: [https:\/\/www.nice.org.uk\/guidance\/ta298]."},{"issue":"5","key":"1630_CR114","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ophtha.2019.09.041","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Salman M, Lee PP, Gatwood JD. Cost-utility analysis of glaucoma medication adherence. Ophthalmology. 2020;127(5):589\u201398.","journal-title":"Ophthalmology"},{"key":"1630_CR115","unstructured":"Alava MH, Pudney S, Wailoo A. Estimating EQ-5D by age and sex for the UK. NICE DSU report 2022. Available from: [https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/DSU%20Age%20based%20utility%20-%20Final%20for%20website.pdf]."},{"key":"1630_CR116","unstructured":"NHS trust and NHS foundation trusts. National Cost Collection for the NHS: 2022\/23 data [Internet] 2024. Available from: [https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/]."},{"key":"1630_CR117","doi-asserted-by":"publisher","unstructured":"Jones K, Weatherly H, Birch S, et al. Unit Costs of Health and Social Care 2023 Manual [Internet]. Kent, UK: Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York) 2024. Available from: [https:\/\/doi.org\/10.22024\/UniKent\/01.02.105685].","DOI":"10.22024\/UniKent\/01.02.105685"},{"key":"1630_CR118","unstructured":"National Institute for Health and Care Excellence (NICE). British National Formulary (BNF). Last updated: May 29, 2024 [Internet] 2024. Available from: [https:\/\/bnf.nice.org.uk\/]."},{"key":"1630_CR119","unstructured":"Department of Health and Social Care. Drugs and pharmaceutical electronic market information tool (eMIT). Last updated: April 5, 2024. [Internet] 2024. Available from: [https:\/\/www.gov.uk\/government\/publications\/drugs-and-pharmaceutical-electronic-market-information-emit]."},{"issue":"6","key":"1630_CR120","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.64.6.6","volume":"64","author":"JS Wolffsohn","year":"2023","unstructured":"Wolffsohn JS, Whayeb Y, Logan NS, Weng R, Group* TIMIA. IMI-global trends in myopia management attitudes and strategies in clinical practice-2022 update. Invest Ophthalmol Vis Sci. 2023;64(6):6.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1630_CR121","unstructured":"Gov.uk. Letter setting out general ophthalmic services fees, payments, optical voucher values and hospital eye service maximum charges from 1 April 2024. Updated 6 January 2025. Available from: [https:\/\/www.gov.uk\/government\/publications\/nhs-general-ophthalmic-service-fees-and-optical-voucher-values-from-april-2024\/letter-setting-out-general-ophthalmic-services-fees-payments-optical-voucher-values-and-hospital-eye-service-maximum-charges-from-1-a]."},{"issue":"4","key":"1630_CR122","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0161-6420(00)00635-7","volume":"108","author":"MM Brown","year":"2001","unstructured":"Brown MM, Brown GC, Sharma S, Busbee B, Brown H. Quality of life associated with unilateral and bilateral good vision. Ophthalmology. 2001;108(4):643\u20137 (discussion 647-648).","journal-title":"Ophthalmology"},{"key":"1630_CR123","unstructured":"The RCOphth NOD Audit. National Electronic Glaucoma Surgery and Visual Field Preservation Audit: Feasibility Report [Internet] 2017. Available from: [https:\/\/www.hqip.org.uk\/wp-content\/uploads\/2018\/04\/Glaucoma-Surgery-Audit-Feasibility-Report.pdf]."},{"key":"1630_CR124","unstructured":"National Institute for Health and Care Excellence (NICE). Latanoprost--netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. Technology appraisal guidance [TA1009]. Published October 2, 2024 Updated 2024. Available from: [https:\/\/www.nice.org.uk\/guidance\/ta1009\/]."},{"issue":"10","key":"1630_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011121","volume":"6","author":"M Violato","year":"2016","unstructured":"Violato M, Dakin H, Chakravarthy U, Reeves BC, Peto T, Hogg RE. Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial. BMJ Open. 2016;6(10):e011121.","journal-title":"BMJ Open"},{"key":"1630_CR126","unstructured":"National Institute for Health and Care Excellence (NICE). Cataracts in adults: management. NICE guideline [NG77]. Published October 26, 2017. Available from: [https:\/\/www.nice.org.uk\/guidance\/ng77\/]."},{"key":"1630_CR127","unstructured":"NHS.uk. Follow-up with a local optometrist. Cataract surgery 2022. Available from: [https:\/\/www.guysandstthomas.nhs.uk\/health-information\/cataract-surgery\/follow-local-optometrist]."},{"key":"1630_CR128","unstructured":"National Institute for Health and Care Excellence (NICE). Clinical knowledge summaries. management scenario: Management of suspected retinal detachment. 2024. Updated August 2024. Available from: [https:\/\/cks.nice.org.uk\/topics\/retinal-detachment\/management\/management-of-suspected-retinal-detachment\/]."},{"key":"1630_CR129","unstructured":"NHS.uk. Retinal detachment surgery and aftercare. Available from: [https:\/\/www.esneft.nhs.uk\/wp-content\/uploads\/2022\/02\/FINAL-05732-21-CPCC-Retinal-Detachment-surgery-and-aftercare.pdf]."},{"key":"1630_CR130","unstructured":"European Medicines Agency. Ranibizumab Summary of product characteristics (SmPC). Available from: [https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lucentis-epar-product-information_en.pdf]."},{"key":"1630_CR131","unstructured":"European Medicines Agency. Aflibercept Summary of product characteristics (SmPC). Available from: [https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eylea-epar-product-information_en.pdf]."},{"issue":"1","key":"1630_CR132","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41433-019-0656-z","volume":"34","author":"HDJ Hogg","year":"2020","unstructured":"Hogg HDJ, Connor A. 10-year trends in English primary care glaucoma prescribing. Eye. 2020;34(1):192\u20136.","journal-title":"Eye"},{"key":"1630_CR133","unstructured":"NHS.uk. Diagnosis: Glaucoma. Available from: [https:\/\/www.nhs.uk\/conditions\/glaucoma\/diagnosis\/]."},{"issue":"1","key":"1630_CR134","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ogla.2022.08.007","volume":"6","author":"DJ Fu","year":"2023","unstructured":"Fu DJ, Ademisoye E, Shih V, McNaught AI, Khawaja AP. Burden of glaucoma in the United Kingdom: a multicenter analysis of United Kingdom glaucoma services. Ophthalmol Glaucoma. 2023;6(1):106\u201315.","journal-title":"Ophthalmol Glaucoma"},{"key":"1630_CR135","unstructured":"The RCOphth NOD Audit. National Electronic Retinal Detachment Surgery Audit: Feasibility Report. 2017."},{"issue":"1","key":"1630_CR136","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014;157(1):9-25.e12.","journal-title":"Am J Ophthalmol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01630-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:02:18Z","timestamp":1787385738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01630-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":136,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01630-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors certify that they meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship.","order":1,"name":"Ethics","label":"Author contribution","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Santen SA, the manufacturer of SYD-101. KSvW, JL, TdM, and FE are employees of Santen. FC, YS, and YP are employees of IQVIA and received funding from Santen to conduct this analysis. The remaining authors declare no financial or non-financial conflicts of interest related to this work.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data supporting the findings of this study are available within the paper and its supplementary information.","order":3,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}